Nymox Pharmaceutical Corporation (NYMX) Jumps On News Of Study Results

Page 2 of 2

With that in mind let’s take a look at the limited hedge fund activity relating to Nymox Pharmaceutical Corporation (NASDAQ:NYMX). Since it is a nano-cap company, it doesn’t enjoy a lot of popularity among larger investors. Among the funds we track, Ken Griffin‘s Citadel Investment Group emerged as the biggest shareholder with a total of 32,075 shares valued at $27,000. The fund cut its position in the stock by 4,300 shares during the first quarter. Clearbridge Investments, LLC, on the other hand, held 1,000 shares worth $1,000, unchanged from three months earlier.

Today’s announcement relating to the company’s studies of fexapotide triflutate for BPH puts it on a good path for growth, with a potential source of revenue in the near future. The success of the Phase 3 studies has made Nymox Pharmaceutical Corporation (NASDAQ:NYMX) a good investment for long term investors.

Disclosure: None

Page 2 of 2